RecruitingPhase 3NCT07088263

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

A Prospective, Multicenter Phase Ⅲ Clinical Trial of Adaptive Chemotherapy for Advanced Breast Cancer After Standard Treatment

Sponsor

Sun Yat-sen University

Enrollment

192 participants

Start Date

Sep 15, 2025

Study Type

INTERVENTIONAL

Conditions

Breast Neoplasms

Summary

The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of advanced breast cancer progressive after standard treatment.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tests an adaptive chemotherapy approach — where the type and doses of chemotherapy are adjusted based on how your tumor is responding — for people with advanced breast cancer that is hormone receptor-positive/HER2-negative (HR+/HER2-) or triple-negative (HR-/HER2-). **You may be eligible if...** - You are 18 or older with a good performance status (ECOG 0 or 1) - You have a confirmed diagnosis of advanced invasive breast cancer (HR+/HER2- or HR-/HER2-) - Your expected survival is more than 3 months - You have measurable disease on imaging **You may NOT be eligible if...** - You have HER2-positive breast cancer - You have already received certain chemotherapy drugs (limits may apply) - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.